Novel cannula design improves large volume auto-injection rates for high viscosity solutions

References

• Abolhassani H, Sadaghiani MS, Aghamohammadi A, et al. (2012). Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis. J Clin Immunol 32:1180–92.
   PubMed Web of Science ®Google Scholar
• Allmendinger A, Fischer S, Huwyler J, et al. (2014). Rheological characterization and injection forces of concentrated protein formulations: an alternative predictive model for non-Newtonian solutions. Eur J Pharm Biopharm 87:318–28.
   PubMed Web of Science ®Google Scholar
• Allmendinger A, Mueller R, Schwarb E, et al. (2015). Measuring tissue back-pressure—in vivo injection forces during subcutaneous injection. Pharm Res 32:2229–40.
   PubMed Web of Science ®Google Scholar
• Bernstein D, Pavord ID, Chapman KR, et al. (2020). Usability of mepolizumab single-use prefilled autoinjector for patient self-administration. J Asthma 57:987–98.
   PubMed Web of Science ®Google Scholar
• Berteau C, Filipe-Santos O, Wang T, et al. (2015). Evaluation of the impact of viscosity, injection volume, and injection flow rate on subcutaneous injection tolerance. Med Devices 8:473–84.
   Google Scholar
• Bittner B, Richter W, Schmidt J. (2018). Subcutaneous administration of biotherapeutics: an overview of current challenges and opportunities. BioDrugs 32:425–40.
   PubMed Web of Science ®Google Scholar
• Dias C, Abosaleem B, Crispino C, et al. (2015). Tolerability of high-volume subcutaneous injections of a viscous placebo buffer: a randomized, crossover study in healthy subjects. AAPS PharmSciTech 16:1101–7.
   PubMed Web of Science ®Google Scholar
• Doughty DV, Clawson CZ, Lambert W, Subramony JA. (2016). Understanding subcutaneous tissue pressure for engineering injection devices for large-volume protein delivery. J Pharm Sci 105:2105–13.
   PubMed Web of Science ®Google Scholar
• Ferguson GT, Cole J, Aurivillius M, et al. (2019). Single-use autoinjector functionality and reliability for at-home administration of benralizumab for patients with severe asthma: GRECO trial results. J Asthma Allergy 12:363–73.
   PubMed Web of Science ®Google Scholar
• Frias JP, Koren MJ, Loizeau V, et al. (2020). The SYDNEY device study: a multicenter, randomized, open-label usability study of a 2-ml alirocumab autoinjector device. Clin Ther 42:94–107.e5.
   PubMed Web of Science ®Google Scholar
• Gibney MA, Arce CH, Byron KJ, Hirsch LJ. (2010). Skin and subcutaneous adipose layer thickness in adults with diabetes at sites used for insulin injections: implications for needle length recommendations. Curr Med Res Opin 26:1519–30.
   PubMed Web of Science ®Google Scholar
• Hirsch L, Byron K, Gibney M. (2014). Intramuscular risk at insulin injection sites – measurement of the distance from skin to muscle and rationale for shorter-length needles for subcutaneous insulin therapy. Diabetes Technol Ther 16:867–73.
   PubMed Web of Science ®Google Scholar
• Hu P, Wang J, Florian J, et al. (2020). Systematic review of device parameters and design of studies bridging biologic-device combination products using prefilled syringes and autoinjectors. AAPS J 22:52.
   PubMed Web of Science ®Google Scholar
• Hudry C, Lebrun A, Moura B, et al. (2017). Evaluation of usability and acceptance of a new autoinjector intended for methotrexate subcutaneous self-administration in the management of rheumatoid arthritis. Rheumatol Ther 4:183–94.
   PubMed Web of Science ®Google Scholar
• Jackisch C, Müller V, Dall P, et al. (2015). Subcutaneous trastuzumab for HER2-positive breast cancer – evidence and practical experience in 7 German centers. Geburtshilfe Frauenheilkd 75:566–73.
   PubMed Web of Science ®Google Scholar
• Jones GB, Collins DS, Harrison MW, et al. (2017). Subcutaneous drug delivery: an evolving enterprise. Sci Transl Med 9:eaaf9166.
   PubMed Web of Science ®Google Scholar
• Kang DW, Oh DA, Fu GY, et al. (2013). Porcine model to evaluate local tissue tolerability associated with subcutaneous delivery of protein. J Pharmacol Toxicol Methods 67:140–7.
   PubMed Web of Science ®Google Scholar
• Laurent PE, Pettis R, Easterbrook W, Berube J. (2006). Evaluating new hypodermic and intradermal injection devices. Med Device Technol 17:16–9.
   PubMedGoogle Scholar
• Mathaes R, Koulov A, Joerg S, Mahler H-C. (2016). Subcutaneous injection volume of biopharmaceuticals—pushing the boundaries. J Pharm Sci 105:2255–9.
   PubMed Web of Science ®Google Scholar
• OECD. (2015). Guidelines for the testing of chemicals, section 4, test no. 404: acute dermal irritation/corrosion. Paris, France: OECD Publishing.
   Google Scholar
• Olofsson S, Norrlid H, Karlsson E, et al. (2016). Societal cost of subcutaneous and intravenous trastuzumab for HER2-positive breast cancer – an observational study prospectively recording resource utilization in a Swedish healthcare setting. Breast 29:140–6.
   PubMed Web of Science ®Google Scholar
• Rini C, Roberts BC, Morel D, et al. (2019). Evaluating the impact of human factors and pen needle design on insulin pen injection. J Diabetes Sci Technol 13:533–45.
   PubMedGoogle Scholar
• Rule S, Collins G, Samanta K. (2014). Subcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma: a time and motion study in the United Kingdom. J Med Econ 17:459–68.
   PubMedGoogle Scholar
• Shapiro R. (2010). Subcutaneous immunoglobulin therapy by rapid push is preferred to infusion by pump: a retrospective analysis. J Clin Immunol 30:301–7.
   PubMed Web of Science ®Google Scholar
• Shire SJ, Shahrokh Z, Liu J. (2004). Challenges in the development of high protein concentration formulations. J Pharm Sci 93:1390–402.
   PubMed Web of Science ®Google Scholar
• Swindle MM, Makin A, Herron AJ, Clubb FJ, Jr, et al. (2012). Swine as models in biomedical research and toxicology testing. Vet Pathol 49:344–56.
   PubMed Web of Science ®Google Scholar
• Swindle M. (2015). Swine in the laboratory: surgery, anesthesia, imaging and experimental techniques. 3rd ed. Boca Raton: CRC Press.
   Google Scholar
• Usach I, Martinez R, Festini T, Peris JE. (2019). Subcutaneous injection of drugs: literature review of factors influencing pain sensation at the injection site. Adv Ther 36:2986–96.
   PubMed Web of Science ®Google Scholar
• Wasserman RL, Melamed I, Kobrynski L, et al. (2011). Efficacy, safety, and pharmacokinetics of a 10% liquid immune globulin preparation (GAMMAGARD LIQUID, 10%) administered subcutaneously in subjects with primary immunodeficiency disease. J Clin Immunol 31:323–31.
   PubMed Web of Science ®Google Scholar
• Watt RP, Khatri H, Dibble ARG. (2019). Injectability as a function of viscosity and dosing materials for subcutaneous administration. Int J Pharm 554:376–86.
   PubMed Web of Science ®Google Scholar
• Wright L, Barnes TJ, Prestidge CA. (2020). Oral delivery of protein-based therapeutics: gastroprotective strategies, physiological barriers and in vitro permeability prediction. Int J Pharm 585:119488.
   PubMed Web of Science ®Google Scholar
• Xiao X, Li W, Clawson C, et al. (2018). Evaluation of performance, acceptance, and compliance of an auto-injector in healthy and rheumatoid arthritic subjects measured by a motion capture system. Patient Prefer Adherence 12:515–26.
   PubMed Web of Science ®Google Scholar